Mucosal co-expression of γ-interferon and interleukin-10 in Crohn's disease and ulcerative colitis;Expression colique de l'interféron-γ et de l'interleukine-10 au cours de la maladie de Crohn et de la rectocolite ulcéro- hémorragique

Presse Medicale

Volumn 34, Issue 1, 2005, Pages 8-12

  Kallel, L ^a   Boubaker, Jalel ^a   Louzir, H ^b   Ben Ahmed, M ^b   Sassi, A ^a   Boubaker, S ^b   Zouari, B ^c   Filali, A ^a  

^a LA RABTA HOSPITAL   (Tunisia)

^b PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^c UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; CYTOKINE RELEASE; FEMALE; GENE AMPLIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; ULCERATIVE COLITIS;

EID: 12544251073     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)83876-x     Document Type: Article

References (29)

1. Autschbach F, Giese T, Gassler N, Sido B, Heuschen G, Heuschen U et al. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch 2002; 441: 500-13.
2. Funakoshi K, Sugimura K, Anezaki K, Bannai H, Ishizuka K, Asakura H. Spectrum of cytokine gene expression in intestinal mucosal lesions of Crohn's disease and ulcerative colitis. Digestion 1998; 59: 73-8.
3. Boirivant M, Marini M, Di Felice G. Functional status of intestinal T lymphocytes, regulatory mechanisms, and their variations in the course of Crohn disease and ulcerative colitis. Ann Ist Super Sanita 1999; 35: 283-9.
4. Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ, Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 285-90.
5. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp immunol 1995; 101: 428-35.
6. Akagi S, Hiyama E, Imamura Y, Takesue Y. Interleukin-10 expression in intestine of Crohn disease. Int Mol Med 2000; 5: 389-95.
7. Gashe C, Bakos S, Dejaco C, Tillinger W. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J Clin Immunol 2000; 20: 362-70.
8. Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ. Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 2003; 52: 981-7.
9. McCarthy J, O'mahony L, O'callaghan L, Sheil B, Vaughan EE, Fitzsimons N. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003; 52: 975-80.
10. Best WR, Becktel JM, Singleton JW, Kern F JR. Development of a Crohn's disease artivity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
11. Truelove SC, Witts LS. Cortisone in ulcerative colitis. Final report on therapeutic trial. Br Med J 1955; 1: 1041-4.
12. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression Methods 2001; 25: 386-401.
13. Schreiber S. Maladies inflammatoires chroniques de l'intestin et immunité. Hepato-Gastro 1999; 6 (hors série): 16-25.
14. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-94.
15. Omata F, Birkenbach M, Matsuzaki S, Christ AD, Blumberg RS. The expression of IL-12 p40 and its homologue, Epstein-Barr virus-induced gene 3, in inflammatory bowel disease. Inflamm Bowel Dis 2001; 7: 215-20.
16. Kakazu T, Hara J, Matsumoto T, Nakamura S, Oshitani N, Arakawa T et al. Type 1 T-helper cell predominance in granulomas of Crohn's disease. Am J Gastroenterol 1999; 94: 2149-55.
17. Macdonald TT, Monteleone G, Pender SL. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000; 51: 2-9.
18. Jenkins D, Seth R, Kummer JA, Scott BB, Hawkey CJ, Robins RA. Differential levels of granzyme B, regulatory cytokines, and apoptosis in Crohn's disease and ulcerative colitis at first presentation. J Pathol 2000; 190: 184-9.
19. Meresse B, Rutgeerts P, Malchow H, Dubucquoi S, Dessaint JP, Cohard M et al. Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut 2002; 50: 25-8.
20. Colpaert S, Vanstraelen K, Liu Z, Penninck F, Geboes K, Rutgeerts P et al. Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn's disease. Clin Immunol 2002; 102: 68-76.
21. Ishizuka K, Sugimura K, Homma T, Matsuzawa J, Mochizuki T, Kobayashi M et al. Influence of interleukin-10 on the interleukin-1 receptor antagonist/interleukin-1 beta ratio in the colonic mucosa of ulcerative colitis. Digestion 2001; 63 (Suppl 1): 22-7.
22. Autschbach F, Braunstein J, Helmke B, Zuna I, Schumann G, Niemir ZI et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol 1998; 153: 121-30.
23. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Stood 1995; 85: 842-51.
24. Shibata Y, Foster LA, Kurimoto M, Okamura H, Nakamura RM, Kawajiri K et al. Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-gamma-inducing factors but enhances NK cell production of IFN-gamma. J Immunol 1998; 161: 4283-8.
25. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. Proinflammatory effects of interleukin-10 during human endotoxemia. J Immunol 2000; 165: 2783-9.
26. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-60.
27. Tilg H, Van Montfrans C, Van Den Ende A, Kaser A, van Deventer SJ, Schreiber S et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002; 50: 191-4.
28. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenteratogy 2000; 119: 1461-72.
29. Agnholt J, Kaltoft K. In situ activated intestinal T cells expanded in vitro-without addition of antigen-produce IFN-gamma and IL-10 and preserve their function during growth. Exp Clin Immunogenet 2001; 18: 213-25.